Clinical trials: Liver Tumour
Pancreatic Neoplasms, Hepatocellular Cancer
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
The purpose of the study is to evaluate whether the novel anti-cancer drug OXY111A is safe and tolerated in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the…
- Conditions
- Pancreatic Neoplasms, Hepatocellular Cancer, Cholangiocarcinoma, Colorectal Neoplasms
- Trial name
- OXY1A (NCT02528526)
- Testing
- OXY111A
- Where
- Switzerland
- Volunteers
- 69 people
- Sponsor
- University of Zurich
Hepatocellular Carcinoma
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with TACE as adjuvant therapy of patients with hepatocellular carcinoma at a high risk of recurrence after radical…
- Trial name
- NCT05161143
- Testing
- Donafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Liver Neoplasms, Neoplasm Metastasis
Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation
A study is being conducted by the University of Rochester Cancer Center (URCC) in which patients with liver cancer will be treated with high dose conformal radiation therapy.
- Trial name
- NCT00178243
- Testing
- 3D Conformal Radiation Therapy and Radiosurgery
- Where
- United States
- Sponsor
- University of Rochester
Pancreatic Cancer, Hepatocellular Cancer
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol 1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine +…
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- NCT05451043
- Testing
- Durvalumab, Gemcitabine, Nab paclitaxel
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- AHS Cancer Control Alberta
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer (CRC)
Clinical Characteristics and Prognosis of Simultaneous Versus Delayed Resection for Synchronous Colorectal Liver Metastasis: A Nationwide Multicenter Study Utilizing Propensity Score Matching Analysis
Colorectal cancer (CRC) often metastasizes to the liver, with synchronous metastases observed in 20% of cases. Surgical resection is the primary treatment, but the impact of simultaneous and staged resections on clinical outcomes…
- Trial name
- NCT07082335
- Where
- China
- Volunteers
- 679 people
- Sponsor
- Shanghai 10th People's Hospital
Liver Cancer
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill liver cancer cells.
- Trial name
- NCT00004248
- Testing
- aldesleukin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
- Trial name
- TREMENDOUS (NCT05557838)
- Testing
- Durvalumab, Tremelimumab
- Where
- 29 sites in China
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
This is a single arm, open-label, non-randomized and single-center phase I/II clinical study, to evaluate the the safety, tolerance and efficacy of Lenvatinib plus Camrelizumab as first-line therapy in patients with advanced…
- Trial name
- NCT04443309
- Testing
- Camrelizumab, Lenvatinib
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Peking Union Medical College Hospital
Liver Cirrhosis, Liver Steatosis
EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI
Aim of this study is to evaluate the correlation between the characteristics detected by the 7T MRI equipment and the histological composition of native explanted livers (group A), liver graft excluded for donation (group B) and…
- Conditions
- Liver Cirrhosis, Liver Steatosis, Hepatocellular Carcinoma, Pancreatic Cancer
- Trial name
- EXLIPSE (NCT04012021)
- Testing
- 7T Magnetic Resonance Imaging
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Cirrhosis, Hepatocellular Carcinoma
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
Although serum alpha-fetoprotein level and abdominal sonography are the main methods to screening hepatocellular carcinoma (HCC) in cirrhotic patients, the adequate time and methods used are not completely well-defined.
- Trial name
- NCT00629421
- Where
- Taiwan
- Volunteers
- 1,200 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis B
Increasing Hepatitis B Screening Among Korean Church Attendees
The purpose of this study is to design an intervention to increase hepatitis B (HBV) screening among Korean Americans. The investigators will design a culturally specific intervention (educational sessions) and test the effect of…
- Trial name
- NCT00760721
- Testing
- Educational Small Group Session
- Where
- United States
- Volunteers
- 1,123 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Hepatocellular Carcinoma
Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma
This study prospectively evaluates the accuracy of the noninvasive diagnostic criteria for hepatocellular carcinoma.
- Trial name
- HCC (NCT00842647)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Sun Yat-sen University
Alcoholism, Alcohol Use Disorder
Impact of Integrating an Addiction Team on Post Liver Transplantation Survival for Alcohol-related Liver Disease and Its Complications.
Investigator seeks to determine wether integrating an addiction team into a liver transplantation unit improves the prognosis of patients with alcohol-related liver disease requiring liver transplantation.
- Conditions
- Alcoholism, Alcohol Use Disorder, Alcohol; Liver
- Trial name
- NCT04964687
- Testing
- Liver transplantation
- Where
- France
- Volunteers
- 616 people
- Sponsor
- University Hospital, Montpellier
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han
Advanced Solid Tumor, Metastatic Breast Cancer
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
- Conditions
- Advanced Solid Tumor, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Metastatic Endometrial Cancer
- Trial name
- NCT06533332
- Testing
- ERX-315
- Where
- 5 sites in Australia
- Volunteers
- 36 people
- Sponsor
- EtiraRx Australia Pty Ltd
Hepatocellular Carcinoma
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in…
- Trial name
- NCT06478693
- Testing
- MT-303, MT-303 +Atezolizumab + Bevacizumab
- Where
- 9 sites in Australia, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Myeloid Therapeutics
Hepatocellular Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
This is a efficacy and safety study of pembrolizumab (MK-3475, KEYTRUDA®) as monotherapy in participants with hepatocellular carcinoma (HCC) in two cohorts: participants with advanced HCC and with no curative option after disease…
- Trial name
- NCT02702414
- Testing
- Pembrolizumab
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer Diagnosis, LungCancer
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
The goal of this observational study is to screen and differentiate common cancers in participants with or without suspicious lesions.
- Conditions
- Cancer Diagnosis, LungCancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT06036563
- Where
- 8 sites in China
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Non-small Cell Lung Cancer, Gastric Cancer
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype. Our hypothesis is that Natural killer T cells may decrease the tumor burden and improve overall survival.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT02562963
- Testing
- natural killer T cell
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Minghui Zhang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.